Form 4: Shattuck Labs Director Granted Stock Options

Shattuck Labs Director Daniel G. Baker was granted options to purchase 66,300 shares of common stock at an exercise price of $0.99.

Summary

• Director Daniel G. Baker of Shattuck Labs, Inc. (STTK) was granted stock options.
• The options allow the purchase of 66,300 shares of the company's common stock.
• The exercise price for these options is $0.99 per share.
• The transaction date for this grant was August 28, 2025.
• The options will vest in three equal annual installments on each of the first three anniversaries of August 28, 2025, contingent on continued service to the Issuer.
• The options have an expiration date of August 28, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued commitment and aligns management's interests with shareholders. It is a standard compensation practice and not indicative of operational performance, but generally viewed favorably for governance.

Positives

• The grant of stock options to Director Daniel G. Baker aligns his interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule over three years encourages continued service and strategic oversight from a key board member.

Negatives

• Potential future dilution of existing shares if the options are exercised, though this is a common aspect of equity compensation.

Risks

• The value of the stock options is contingent on the future market price of Shattuck Labs' common stock exceeding the exercise price of $0.99.
• The vesting of the options is subject to Daniel G. Baker's continued service to the Issuer, meaning unvested options could be forfeited if service ceases.

Future Outlook

The options are designed to vest in three equal annual installments on each of the first three anniversaries of August 28, 2025, contingent on the reporting person's continued service. This indicates an expectation of continued engagement from the director.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, aiming to align executive and board interests with long-term shareholder value creation. This form of equity compensation is prevalent among publicly traded companies, particularly those in growth-oriented sectors like Shattuck Labs.

Comparison to Industry Standards

• The grant of 66,300 stock options to a director, with a vesting schedule tied to continued service, is consistent with typical equity compensation packages observed in the biotechnology sector for non-employee directors.
• While specific comparable companies or projects are not detailed in the filing, such grants are standard for retaining and incentivizing experienced board members in companies of similar market capitalization and development stage.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aligned director incentives; minor potential future dilution if options are exercised.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The options will vest in three equal annual installments on the first three anniversaries of August 28, 2025.
• Daniel G. Baker may exercise the vested options to purchase common stock at $0.99 per share before the expiration date of August 28, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director, which is a standard compensation practice aimed at aligning interests. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Shattuck Labs, STTK, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant